CytRx - CYTR Stock Forecast, Price & News

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on CytRx in a report on Tuesday, August 9th. They set a "hold" rating on the stock.

CytRx Trading Down 13.6 %

Shares of CYTR Stock traded down $0.01 during trading hours on Monday, reaching $0.09. The stock had a trading volume of 34,424 shares, compared to its average volume of 109,227. The stock has a fifty day simple moving average of $0.10. CytRx has a 12 month low of $0.05 and a 12 month high of $0.86.

CytRx (NASDAQ:CYTR - Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.04) earnings per share (EPS) for the quarter.